Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$17.3 million.

  • Arcturus Therapeutics Holdings' Free Cash Flow rose 2731.09% to -$17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.6 million, marking a year-over-year increase of 481.86%. This contributed to the annual value of -$60.4 million for FY2024, which is 18759.52% down from last year.
  • Arcturus Therapeutics Holdings' Free Cash Flow amounted to -$17.3 million in Q3 2025, which was up 2731.09% from -$5.8 million recorded in Q2 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Free Cash Flow peaked at $156.5 million during Q4 2022, and registered a low of -$51.2 million during Q1 2022.
  • Moreover, its 5-year median value for Free Cash Flow was -$30.5 million (2024), whereas its average is -$13.4 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Free Cash Flow skyrocketed by 45871.15% in 2022, and later tumbled by 50850.44% in 2025.
  • Arcturus Therapeutics Holdings' Free Cash Flow (Quarter) stood at -$43.6 million in 2021, then skyrocketed by 458.71% to $156.5 million in 2022, then tumbled by 100.96% to -$1.5 million in 2023, then soared by 81.12% to -$284000.0 in 2024, then plummeted by 6002.82% to -$17.3 million in 2025.
  • Its last three reported values are -$17.3 million in Q3 2025, -$5.8 million for Q2 2025, and -$35.3 million during Q1 2025.